FDA slaps Flori­da's Al­lay Phar­ma­ceu­ti­cals with warn­ing let­ter over vague re­spons­es to drug po­ten­cy is­sues

In­ad­e­quate re­spons­es to find­ings of po­ten­cy dis­crep­an­cies, blend­ing is­sues and out-of-spec­i­fi­ca­tion sam­ples dur­ing a May 2020 in­spec­tion re­cent­ly land­ed tablet man­u­fac­tur­er Al­lay Phar­ma­ceu­ti­cals with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER